medtech-devices-diagnostics theme · 18 dossiers

TAVR disruptor at fresh 52w-high but on momentum not news, into a live $250M ATM seller, real binary ~2028 idiosyncratic, MATURING.

Broken growth (new patient starts -10-20% seq) bouncing into ADA on RSI 82.3 parabolic off a busted base; litigation circling event-relief, not a trend.

Post-ASMS product-cycle pop peaked ~$63 and rolling over (-6%), organic -4.4%, trades above raised consensus wait-for-a-higher-low fade.

Liquid-biopsy ACCELERATING but late re-rated +30% into the $136 consensus PT as the upgrade cluster completed; DXCM cleaner.

Defensive med-tech turnaround, MATURING character, no narrative velocity; recovery bounce toward a depressed PT cluster wrong archetype for size.

Med-device turnaround re-rating banked price above every raised PT, organic only +1.3%, idiosyncratic (no peer cluster); no edge today.

Post-COVID turnaround re-rate cooling, both catalysts public, no life-science-tools cluster confirmation, catalyst desert to ~Aug probe-only at best.

Broken legacy-diagnostics downtrend Q1 -10.5% miss + guide cut, near 52w low, below all MAs; value trap, track for a base above $9.92.

Implantable-CGM ADA-de-risked but fell INTO its catalyst (below 50-day, supply>demand), micro-cap value-trap DXCM is the cluster pick.

Spatial-biology re-rate but Atera revenue is a 2027 story, Q1 -3% YoY, -7.3% outside-reversal off the high stretched, post-catalyst, idiosyncratic.

Busted growth -49% on a 12% guide cut, dead-cat bounce off $32 low, reimbursement leg broken gated on next ARR print, not a fresh setup.